Furthermore, simvastatin has demonstrated dual functionality in HCC by not only mitigating tumor growth but also augmenting the sensitivity of HCC cells to sorafenib through modulation of SREBP2-mediated cholesterol biosynthesis pathways [40]. This evidence concerns the gene SREBF2 and hepatocellular carcinoma.